Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.

AIM The combination of ephedrine and caffeine has been used in herbal products for weight loss and athletic performance-enhancement, but the pharmacokinetic profiles of these compounds have not been well characterized. This study aimed to develop a mechanistic model describing ephedrine, norephedrine, and caffeine pharmacokinetics and their interactions in healthy subjects. METHODS The pharmacokinetic model was developed based on the simultaneous modelling using plasma samples gathered from two clinical trials. The treatments consisted of single-doses of pharmaceutical caffeine and ephedrine, given alone or together, and an herbal formulation containing both caffeine and ephedrine. We used a mixed-effect statistical model and the program NONMEM to take account of intersubject variability. RESULTS Three hundred and seventy-nine ephedrine, 352 norephedrine, 417 caffeine plasma concentrations and 40 ephedrine urine concentrations were obtained from 24 subjects. A one-compartment model with first-order absorption described the caffeine data. Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%). A four-compartment model described the pharmocokinetics of ephedrine and norephedrine. Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%). Nonlinearity in the conversion of ephedrine to norephedrine was observed. Different models showed that the simultaneous administration of caffeine, or the amount of caffeine in the absorption compartment, was associated with a slower rate of absorption of ephedrine. A 32% greater relative bioavailability of herbal compared with pharmaceutical ephedrine administration was observed. CONCLUSIONS We describe a mechanistic model for ephedrine, norephedrine and caffeine pharmacokinetics and their interactions. The relative bioavailability of ephedrine differed between the herbal supplement compared with the pharmaceutical formulation. Concomitant ingestion of caffeine slowed the absorption rate of ephedrine, which is mainly related to the amount of the former in the absorption compartment. A saturable process appears to be involved in the metabolism of ephedrine to norephedrine.

[1]  A. Pipe.  Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance , 2004 .

[2]  N. Benowitz,et al.  Enhanced Stimulant and Metabolic Effects of Combined Ephedrine and Caffeine , 2004, Clinical pharmacology and therapeutics.

[3]  J. Biller,et al.  Ischemic stroke after using over the counter products containing ephedra , 2004, Journal of the Neurological Sciences.

[4]  Paul G Shekelle,et al.  Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. , 2003, JAMA.

[5]  R. Hoffman,et al.  Ephedrine‐Induced Cardiac Ischemia: Exposure Confirmed with a Serum Level , 2003, Journal of toxicology. Clinical toxicology.

[6]  N. Benowitz,et al.  Pharmacology of ephedra alkaloids and caffeine after single‐dose dietary supplement use , 2002, Clinical pharmacology and therapeutics.

[7]  T. Andersen,et al.  Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. , 2001, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[8]  N. Benowitz,et al.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. , 2001, The New England journal of medicine.

[9]  S. Heymsfield,et al.  An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial , 2001, International Journal of Obesity.

[10]  R. Purssell,et al.  Cardiovascular toxicity after ingestion of "herbal ecstacy". , 1999, The Journal of emergency medicine.

[11]  S. Gardner,et al.  Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). , 1998, Therapeutic drug monitoring.

[12]  T. Theoharides.  Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. , 1997, Journal of clinical psychopharmacology.

[13]  M. A. Marx,et al.  Pharmacokinetics and Cardiovascular Effects of Ma‐Huang (Ephedra sinica) in Normotensive Adults , 1997, Journal of clinical pharmacology.

[14]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[15]  K. Nolte,et al.  Stroke associated with ephedrine use , 1993, Neurology.

[16]  T. Yaksh,et al.  Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. , 1993, Pharmacological reviews.

[17]  S. Toubro,et al.  Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. , 1991, Metabolism: clinical and experimental.

[18]  L. Powell,et al.  Dose‐dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function , 1990, Clinical pharmacology and therapeutics.

[19]  S. Spielberg,et al.  A urinary metabolite ratio that reflects systemic caffeine clearance , 1987, Clinical pharmacology and therapeutics.

[20]  E. H. Twizell.  The mathematical modeling of metabolic and endocrine systems: E.R. Carson, C. Cobelli and L. Finkelstein John Wiley and Sons, Chichester, Sussex, UK, 394 pp., £45.15, 1983 , 1984 .

[21]  S. Schenker,et al.  Impaired elimination of caffeine by oral contraceptive steroids. , 1980, The Journal of laboratory and clinical medicine.

[22]  J. Paterson,et al.  The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. , 1976, British journal of clinical pharmacology.

[23]  P. Sever,et al.  The metabolism of (−)-ephedrine in man , 1975, European Journal of Clinical Pharmacology.

[24]  H. Akaike.  A new look at the statistical model identification , 1974 .

[25]  J. Wagner,et al.  Urinary excretion of ephedrine in man without pH control following oral administration of three commercial ephedrine sulfate preparations. , 1971, Journal of pharmaceutical sciences.

[26]  G. Wilkinson,et al.  Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. , 1968, Journal of pharmaceutical sciences.

[27]  J. Cyong,et al.  Population pharmacokinetic analysis of ephedrine in Kampo prescriptions: a study in healthy volunteers and clinical use of the pharmacokinetic results. , 2001, International journal of clinical pharmacology research.

[28]  S. Blumen,et al.  Alien hand sign in Creutzfeldt-Jakob disease , 2000 .

[29]  M. Samsom,et al.  Coffee and gastrointestinal function: facts and fiction. A review. , 1999, Scandinavian journal of gastroenterology. Supplement.

[30]  Adverse events associated with ephedrine-containing products--Texas, December 1993-September 1995. , 1996, MMWR. Morbidity and mortality weekly report.

[31]  L. Malspeis,et al.  Biotransformation of D(-)-ephedrine and L(+)-ephedrine in the rabbit, in vivo and in vitro. , 1977, Drug metabolism and disposition: the biological fate of chemicals.